Piramal Pharma Share Price Target 2024-2030 Today Update, Business Profile, Fundamentals & Quarterly Results

The Piramal Group of businesses includes Piramal Pharma, which is registered in Mumbai, Maharashtra. Pharmaceutical products are produced and sold by Piramal Pharma Limited. The business has a global and domestic serving area. Piramal Pharma’s global distribution network enables this Indian pharmaceutical company to have a significant impact on the international stage. PPL Pharma has manufacturing facilities in 17 locations around the world and more than 100 distribution networks worldwide.

Piramal Pharma Share Price Target 2024-2030

Piramal Pharma is an essential component of the Mumbai, Maharashtra-based Piramal business Group. Their pharmaceuticals are manufactured and distributed by this company. This service provider has a global and local presence everywhere. This has made Piramal Pharma significant on a global scale everywhere. Piramal Pharma is a global company that manufactures one-of-a-kind goods and provides customers with a comprehensive array of pharmaceutical services.

Piramal Pharma Share Price Target Today Update

• Piramal Pharma’s share price today began at Rs 123.55 per share, and the stock has shown no signs of fluctuation on the stock market throughout the day. The US Food and Drug Administration (FDA) recently granted Piramal Pharma company approval for its Lexington facility.
• After conducting an inspection at the Piramal Pharma Lexington Plant, authorities made two observations. Nandini Piramal, chairperson of Piramal Pharma, revealed the company’s plan to invest Rs 1,000 crore over the next 18 months to boost the business’s growth.
• In the interview that took place on December 8, 2023, Nandini Piramal provided a more in-depth explanation of the means by which the business would make investments to maintain its growth rate and increase its brownfield capacity.

Check Here:-

Adani Ports Share Price Target

Samvardhana Motherson Share Price Target

Piramal Pharma Business Profile

Piramal Pharma Limited (PPL) is one of the Piramal group’s businesses. The company entered the pharmaceutical industry in 1988 by purchasing Nicholas Laboratories, which it expanded through various strategies, including mergers and acquisitions. The company sold its local formulations division to Abott for USD 3.7 billion this year, and Super Religare Laboratories purchased its diagnostics division (SRL).

• CDMO: Three of the company’s 13 locations are in North America, two are in Europe, and seven are in India. The other two are used for the operation. It is one of the top three CDMO companies in the area, but when it comes to capabilities for both finished drugs and active pharmaceutical ingredients, it ranks 13th globally. The company has about 500 regular customers who live in various parts of the world.
• CHG: Inhalation anesthesia, anesthesia and pain management, intrathecal therapy, and other injectables are just a few of the company’s product categories. It is the world’s fourth-largest manufacturer of inhaled anesthesia. More than 6,000 hospitals are among its customers. The item portfolio comprises of in excess of 40 contributions, which are gathered as follows; Inward breath Sedation (58%), Injectable Sedation and torment the board (17%), Intrathecal Treatment (16%), and different items (9%).

India Consumer Healthcare

Through this globalization strategy, the company owns diverse assets of vertically integrated manufacturing capabilities, allowing it to launch 13 of its development SKUs and simultaneously have 11 filed, 13 under development, and as many as 13 yet-to-be-unveiled products. The domain that the company controls spans over 100 nations.

Joint Venture

This organization has a 49% possession interest in a joint endeavor with Allergan India Pvt. Ltd., one of India’s leading manufacturers of ophthalmic formulations (Avvyie, a US pharmaceutical company, owns 51% of the company). Glaucoma, dry eye, infections, and inflammation are areas where the company excels. Ozurdex, Combigan, Lumigan, Alphagan, and Predforte are important brands.

Piramal Pharma Fundamentals & Quarterly Results

Market Cap	₹20,967 Cr.
Current Price	₹158
52 Week High/Low	₹167 / ₹87.5
Stock P/E	1,335
Book Value	₹59.8
Dividend Yield	0.07%
ROCE	5.52%
ROE	0.21%
Face Value	₹10.0
Debt to Equity	0.60
Debt Preceding Year	₹5,637 Cr.
Current Debt	₹4,710 Cr.
Reserves	₹6,588 Cr.
EPS	₹0.13
EPS Last Year	₹0.13
Pledged Percentage	0.00%
FCF Previous Annual	₹ -461 Cr.
EV/EBITDA	17.6
Industry P/E	36.2
Piotroski Score	9.00
Earnings Yield	2.72%
Sales Growth 5 Years	Not Provided

Check Here:-

Tata Investment Share Price Target

Mazagon Dock Share Price Target

Piramal Pharma Quarterly Results

Quarter	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Sales	1,482	1,720	1,716	2,164	1,749	1,911	1,959	2,552
Expenses	1,465	1,547	1,629	1,812	1,617	1,646	1,690	2,022
Operating Profit	17	173	87	351	132	266	268	530
OPM %	1%	10%	5%	16%	8%	14%	14%	21%
Other Income	92	50	98	32	53	68	43	8
Interest	62	83	95	104	119	110	106	114
Depreciation	162	166	164	184	174	185	186	196
Profit before tax	-115	-26	-74	95	-107	40	19	227
Tax %	5%	-42%	-22%	47%	8%	87%	48%	55%
Net Profit	-109	-37	-90	50	-99	5	10	101
EPS in Rs		-0.28	-0.68	0.38	-0.75	0.04	0.08	0.77

CAGR Report

Metric	10 Years	5 Years	3 Years	TTM	1 Year
Compounded Sales Growth	–	–	9%	15%	–
Compounded Profit Growth	–	–	-73%	108%	–
Stock Price CAGR	–	–	–	–	76%
Return on Equity	–	–	1%	–	0%

Piramal Pharma Shareholding Pattern

Quarter	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoters	34.78%	34.78%	34.78%	35.02%	35.02%	35.02%
FIIs	41.29%	39.28%	35.01%	32.37%	32.51%	30.58%
DIIs	5.26%	4.98%	5.48%	8.01%	9.68%	12.12%
Public	18.27%	20.57%	24.32%	24.21%	22.41%	21.89%
Others	0.39%	0.39%	0.39%	0.38%	0.38%	0.37%
No. of Shareholders	2,29,960	2,41,359	2,77,270	3,00,606	2,92,312	2,97,996

Piramal Pharma Share Price Target 2024-2030 Forecast

Year	Initial Target
2024	200
2025	261
2026	326
2027	367
2028	420
2029	479
2030	530

Piramal Pharma Share Price Target 2025

Month	Target
January	213
February	207
March	199
April	205
May	211
June	225
July	233
August	245
September	257
October	248
November	256
December	261

Piramal Pharma Share Price Target 2026

Month	Target
January	267
February	260
March	254
April	262
May	274
June	287
July	296
August	309
September	315
October	311
November	319
December	326

Piramal Pharma Share Price Target 2027

Month	Target
January	325
February	319
March	312
April	318
May	328
June	337
July	344
August	357
September	350
October	345
November	353
December	367

Piramal Pharma Share Price Target 2028

Month	Target
January	375
February	368
March	362
April	340
May	345
June	360
July	385
August	400
September	396
October	406
November	412
December	420

Check Here:-

Bank Of India Share Price Target

Wockhardt Share Price Target

Piramal Pharma Share Price Target 2029

Month	Target
January	429
February	421
March	415
April	390
May	405
June	419
July	430
August	441
September	459
October	455
November	467
December	479

BPCL Share Price Target 2030

Month	Target
January	489
February	470
March	450
April	458
May	478
June	490
July	500
August	511
September	520
October	513
November	521
December	530

Points Before Investing in Piramal Pharma Stock

• India’s and the world’s pharmaceutical industries are huge, and the potential Indian market and its manufacturers make things even more interesting for investors in pharmaceutical companies.
• In its December quarter (Q3 FY24), Piramal Pharma Ltd. reported a net profit of Rs 10.11 crores and revenue growth of 14% year over year.
• Piramal Pharma’s EBIDTA was reported at Rs. 330 crores, representing a 94% annual growth rate. PPL Pharma had an Ebidta Margin of 17%.
• These results point to the company’s overall efficiency as well as other factors like lower raw material costs.
• Piramal Pharma Offer Cost target is set at Rs 165 and the Motilal Oswal dealer firm and offer market master has kept up with its “‘Purchase” status for the NSE PPL Pharma’ in its proclamation toward the beginning of February 2024.

Final Words

The Piramal Pharma Share Price history recommends us an entirely unsound nature of the stock. NSE PPL Pharma stock went from Rs 169 as its opening price point to Rs 62 per share just six months after it was listed on the stock exchange. This occurred in just one year and seven months of trading on the stock exchange. However, the Piramal Pharma Share has been recovering since March 2023, when it reached its all-time low stock price. As of this writing, on March 12, 2024, the share is currently trading at Rs 123.35 per share.